Meta‐analysis of randomized, double‐blind, placebo‐controlled trials of melatonin in Alzheimer's disease
- 19 September 2016
- journal article
- review article
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 32 (1) , 50-57
Abstract
Objective: This is a meta‐analysis of randomized controlled trials (RCTs) of the efficacy of melatonin in Alzheimer's disease (AD).Methods: Both English (PubMed, PsycINFO, Embase, Cochrane Library databases, and the Cochrane Controlled Trials Register) and Chinese (WanFang Database, Chinese Biomedical Database, and China Journal Net) databases were systematically and independently searched by two authors from their inception until 1 March 2016. Weighted and standard mean differences (SMDs), risk ratio (RR) ±95% confidence intervals (CIs) were calculated. In all cases, the random effects model was used.Results: Seven studies (n = 462) with the duration ranging from 10 days to 24 weeks were identified and analyzed. AD patients receiving melatonin treatment showed prolonged total sleep time at night (n = 305; SMD: 0.26, 95% CI: 0.01 to 0.51, I2 = 9%, p = 0.04). Melatonin did not improve cognitive abilities assessed by the mini‐mental state examination and the Alzheimer's Disease Assessment Cognitive Subscale. The discontinuation rate was similar between the melatonin and placebo groups (n = 453, RR = 0.77, 95% CI: 0.51 to 1.16, I2 = 0%, p = 0.21).Conclusion: Melatonin appears to be effective and safe in improving sleep quality in patients with AD. Copyright © 2016 John Wiley & Sons, Ltd.Keywords
This publication has 24 references indexed in Scilit:
- Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trialsBMJ, 2011
- Melatonin Fails to Improve Sleep or Agitation in Double-Blind Randomized Placebo-Controlled Trial of Institutionalized Patients With Alzheimer DiseaseThe American Journal of Geriatric Psychiatry, 2009
- Melatonin and Bright‐Light Treatment for Rest–Activity Disruption in Institutionalized Patients with Alzheimer's DiseaseJournal of the American Geriatrics Society, 2008
- Grading quality of evidence and strength of recommendationsBMJ, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementiaInternational Journal of Geriatric Psychiatry, 2002
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- “Mini-mental state”Journal of Psychiatric Research, 1975